This delivery system was based on EGFR overexpression in many cancers, including in up to 90% of ovarian cancers [169], and utilized the FDA-approved monoclonal antibody, cetuximab (C225), to specifically target EGFR for the delivery of p53 to ovarian cancer cells [73]. This evidence concerns the gene EGFR and ovarian carcinoma.